

Please cancel claims 9-33 and 39-52, and amend claims 5 and 8, as reflected in the following listing of claims. This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A cyclic peptide having the formula:



wherein Z_1 and Z_2 are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds; wherein Z_1 and Z_2 independently range in size from 1 to 10 residues; and wherein X and Y are independently selected from the group consisting of amino acid residues, wherein a disulfide bond is formed between residues X and Y.

2. (Original) A cyclic peptide according to claim 1, the peptide has an N-terminal acetyl, formyl or mesyl group.

3. (Original) A cyclic peptide according to claim 1, wherein X and Y are each independently selected from the group consisting of cysteine, penicillamine, β,β -tetramethylene cysteine, β,β -pentamethylene cysteine, β -mercaptopropionic acid, β,β -pentamethylene- β -mercaptopropionic acid, 2-mercaptobenzene, 2-mercaptoaniline and 2-mercaptoproline.

4. (Original) A cyclic peptide according to claim 1, wherein X and Y are cysteine residues.

5. (Currently Amended) A cyclic peptide according to claim 1, wherein the cyclic peptide comprises a sequence selected from the group consisting of: N-Ac-CHAVC-NH₂ (SEQ ID NO:10), N-Ac-CHAVC-Y-NH₂ (SEQ ID NO:84), N-N-Ac-CHAVDC-NH₂ (SEQ ID NO:20), N-Ac-CHAVDIC-NH₂ (SEQ ID NO:50), N-Ac-CHAVDINC-NH₂ (SEQ ID NO:51), N-Ac-CHAVDINGC-NH₂ (SEQ ID NO:76), N-Ac-CAHAVC-NH₂ (SEQ ID NO:22), N-Ac-CAHAVDC-NH₂ (SEQ ID NO:26), N-Ac-CAHAVDIC-NH₂ (SEQ ID NO:24), N-Ac-CRAHAVDC-NH₂ (SEQ ID NO:28), N-Ac-CLRAHAVC-NH₂ (SEQ ID NO:30), N-Ac-CLRAHAVDC-NH₂ (SEQ ID NO:32), N-Ac-CSHAVC-NH₂ (SEQ ID NO:36), N-Ac-CFSHAVC-NH₂ (SEQ ID NO:85), N-Ac-CLFSHAVC-NH₂ (SEQ ID NO:86), N-Ac-CHAVSC-NH₂ (SEQ ID NO:38), N-Ac-CSHAVSC-NH₂ (SEQ ID NO:40), N-Ac-CSHAVSSC-NH₂ (SEQ ID NO:42), N-Ac-CHAVSSC-NH₂ (SEQ ID NO:44), N-Ac-KHAVD-NH₂ (SEQ ID NO:12), N-Ac-DHAVK-NH₂ (SEQ ID NO:14), N-Ac-KHAVE-NH₂ (SEQ ID NO:16), N-Ac-AHAVDI-NH₂ (SEQ ID NO:34), N-Ac-SHAVDSS-NH₂ (SEQ ID NO:77), N-Ac-KSHAVSSD-NH₂ (SEQ ID NO:48), N-Ac-CHAVC-S-NH₂ (SEQ ID NO:87), N-Ac-S-CHAVC-NH₂ (SEQ ID NO:88), N-Ac-CHAVC-SS-NH₂ (SEQ ID NO:89), N-Ac-S-CHAVC-S-NH₂ (SEQ ID NO:90), N-Ac-CHAVC-T-NH₂ (SEQ ID NO:91), N-Ac-CHAVC-E-NH₂ (SEQ ID NO:92), N-Ac-CHAVC-D-NH₂ (SEQ ID NO:93), N-Ac-CHAVYC-NH₂ (SEQ ID NO:94), CH₃-SO₂-HN-CHAVC-Y-NH₂ (SEQ ID NO:95), CH₃-SO₂-HN-CHAVC-NH₂ (SEQ ID NO:96), HC(O)-NH-CHAVC-NH₂ (SEQ ID NO:96), N-Ac-CHAVPen-NH₂ (SEQ ID NO:97), N-Ac-PenHAVC-NH₂ (SEQ ID NO:98) and N-Ac-CHAVPC-NH₂ (SEQ ID NO:99).

6. (Original) A cyclic peptide according to claim 5, wherein the cyclic peptide has an N-terminal acetyl group or CH₃-SO₂- group, and a C-terminal amide group.

7. (Original) A cyclic peptide comprising a dimer or multimer of the sequence His-Ala-Val.

8. (Currently Amended) A cell adhesion modulating agent comprising a cyclic peptide according to ~~any one of claims 1-7~~ claim 1.

9-33. Canceled

34. (Original) A method for modulating vascular smooth muscle cell migration, comprising contacting a vascular smooth muscle cell with a cell adhesion modulating agent according to claim 8, and thereby modulating vascular smooth muscle cell migration.

35. (Original) A method for modulating vascular smooth muscle cell apoptosis, comprising contacting a vascular smooth muscle cell with a cell adhesion modulating agent according to claim 8, and thereby modulating vascular smooth muscle cell apoptosis.

36. (Original) A method for preventing the formation or advance of restenosis, comprising contacting a cadherin expressing cell with a cell adhesion modulating agent according to claim 8, and thereby preventing the formation or advance of restenosis.

37. (Original) A method for maintaining vessel luminal area following vascular trauma, comprising contacting a cadherin expressing cell with a cell adhesion modulating agent according to claim 8, and thereby maintaining vessel luminal area following vascular trauma.

38. (Original) A method for treating a traumatized vessel, comprising contacting a cadherin expressing cell with a cell adhesion modulating agent according to claim 8, and thereby treating a traumatized vessel.

39-52. (Canceled)

53. (Original) An implantable medical device or material linked to, coated with or having interspersed within, a cell adhesion modulating agent according to claim 8.

53. (Original) An implantable medical device or material linked to, coated with or having interspersed within, a cell adhesion modulating agent according to claim 8.

54. (Original) The medical device of claim 53, wherein the medical device is selected from the group consisting of a balloon, stent, shunt, catheter, stent graft, vascular graft, vascular patch, filter, adventitial wrap, intraluminal paving system, cerebral stent, cerebral aneurysm filter coil, myocardical plug, pacemaker lead, dialysis access graft, and heart valve.